Navigation Links
'Reassuring' findings released in national study of influenza vaccine safety in pregnancy
Date:9/23/2013

SAN DIEGO, CA Researchers from Boston University's Slone Epidemiology Center and UC San Diego, in collaboration with the American Academy of Allergy Asthma and Immunology (AAAAI), have found 'reassuring' evidence of the H1N1 influenza vaccine's safety during pregnancy. The national study, which was launched shortly after the pandemic H1N1 influenza outbreak of 2009 and funded by the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), will be summarized in two companion papers published online this month in the journal, Vaccine.

Despite federal health authorities' recommendations that all pregnant women be vaccinated for influenza in order to avoid serious complications of flu infection, it is estimated that fewer than 50 percent of women follow this advice, largely because they were concerned about the effects flu vaccines might have on the developing baby. Since it was anticipated that the 2009 pandemic H1N1 influenza outbreak could be particularly severe, it was important to gather data on the safety of this vaccine in pregnancy. Therefore, a national study was launched by the Vaccines and Medications in Pregnancy Surveillance System (VAMPSS), a collaboration between investigative teams at Boston University and UC San Diego, and coordinated by the American Academy of Allergy, Asthma and Immunology.

One investigative team, from Boston University, interviewed 4,191 mothers from four regional centers in the U.S. who had either delivered a baby with one of 41 specific birth defects or delivered an infant without defects. They compared the use of influenza vaccine in the two groups during the 2009 - 2011 seasons. In their analysis of birth defects, Dr. Carol Louik, ScD, lead investigator of the BU team, stated "We found no evidence of an increase in risk for the most commonly-occurring specific major birth defects, which were the focus of the study, if a woman received the flu shot in pregnancy. Concerns about the risk of specific birth defects was a critical question that has not been considered very much until now, and our data are reassuring."

The team also compared the risk of preterm delivery in vaccinated versus unvaccinated women. While the team did observe a slight increase in preterm delivery rates among pregnant women who received the H1N1 vaccine specifically during the 2009 - 2010 season, vaccinated women overall only delivered an average of two days earlier compared to the unvaccinated group. For those vaccinated during the 2010 - 2011 season, the situation was reversed, and vaccinated women were less likely to deliver a preterm baby.

The other VAMPSS research team from UC San Diego followed 1,032 pregnant women across the U.S. and Canada who either chose to receive an influenza vaccine or were not vaccinated during one of the three seasons from 2009 - 2012. Women were recruited through MotherToBaby, a service of the non-profit Organization of Teratology Information Specialists (OTIS) that provides counseling to the public about pregnancy and breastfeeding exposures. Researchers found that women vaccinated during pregnancy were no more likely to experience miscarriage, have a baby born with a birth defect, or have a baby born smaller than normal compared with those who did not receive a vaccination. In addition, those who were vaccinated delivered infants three days earlier than unvaccinated women.

"The overall results of the study were quite reassuring about the safety of the flu vaccine formulations that contained the pandemic H1N1 strain given in these three seasons," said Christina Chambers, PhD, lead investigator of UC San Diego's team. "We believe our study's results can help women and their doctors become better informed about the benefits and risks of vaccination during pregnancy."


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. New findings on tree nuts and health presented at the Experimental Biology Meeting in Boston, Mass.
2. Surprising findings on hydrogen production in green algae
3. Findings to help in design of drugs against virus causing childhood illnesses
4. ACMG releases report on incidental findings in clinical exome and genome sequencing
5. New findings in the search for genetic clues to insulin production
6. The findings between DNMs and autism provides global view of mutability on human diseases
7. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
8. Verinata Health Announces New Findings At The American Society Of Human Genetics
9. New findings on gene regulation and bone development
10. New findings on protein misfolding
11. Blue Ribbon Panel unveils findings on logistical improvements to support Antarctic science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
Breaking Biology News(10 mins):
(Date:3/29/2017)... ... March 29, 2017 , ... ComplianceOnline, the leading governance, risk ... its 3rd Annual Medical Device Summit 2017 venue and speaker lineup. The Summit will ... in Boston, MA. , The Omni Parker House Hotel, which is located at 60 ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... ... March 29, 2017 , ... ACEA Biosciences, a privately owned ... travel award to noteworthy scientists who will be presenting research using ACEA Biosciences’ ... of awards are being given to two postdoctoral fellows studying pathogen capture by ...
(Date:3/29/2017)... ... March 29, 2017 , ... Bactana Animal Health, a company developing natural products ... through enhancement of the gut microbiota, today announced the closing of its first round ... York-based Sustainable Income Capital Management, LLC and a number of private investors. The company ...
Breaking Biology Technology: